Direct-to-Consumer Advertising and the Demand for Cholesterol-Reducing Drugs

B-Tier
Journal: Journal of Law and Economics
Year: 2002
Volume: 45
Issue: S2
Pages: 673-690

Authors (3)

John E. Calfee (not in RePEc) Clifford Winston (Brookings Institution) Randolph Stempski (not in RePEc)

Score contribution per author:

0.670 = (α=2.01 / 3 authors) × 1.0x B-tier

α: calibrated so average coauthorship-adjusted count equals average raw count

Abstract

In August 1997, the Food and Drug Administration (FDA) reinterpreted its advertising regulations to ease limits on the use of broadcast media when advertising prescription drugs directly to consumers. We estimate the effect of direct-to-consumer advertising on demand, using 1995-2000 data from the market for the statin class of cholesterol-reducing drugs. We find no statistically significant effect from any form of advertising and promotion on new statin prescriptions or renewals and no evidence of adverse market effects from advertising or the FDA policy change. We did find evidence, however, that television advertising increased the proportion of cholesterol patients who had been successfully treated, which suggests that advertising reinforces compliance with drug therapy.

Technical Details

RePEc Handle
repec:ucp:jlawec:doi:10.1086/374704
Journal Field
Industrial Organization
Author Count
3
Added to Database
2026-01-25